Literature DB >> 12118112

Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability.

Giovanni Lanza1, Roberta Gafà, Iva Maestri, Alessandra Santini, Maurizio Matteuzzi, Luigi Cavazzini.   

Abstract

Detection of colorectal carcinomas with high-frequency microsatellite instability (MSI-H) is clinically important for several reasons. Recent studies suggested that immunohistochemical analysis of MLH1 and MSH2 expression is a rapid and accurate method for identifying large bowel tumors of the MSI-H phenotype. In this study, we evaluated by immunohistochemistry MLH1 and MSH2 protein expression in 132 MSI-H, 23 MSI-L (low-frequency MSI), and 150 microsatellite stable (MSS) colorectal adenocarcinomas. Loss of MLH1 or MSH2 expression was detected in 120 (90.9%) MSI-H carcinomas, whereas all MSI-L and MSS tumors showed normal expression of both proteins. Lack of MLH1 nuclear staining was observed much more often than absence of MSH2 nuclear staining (106 and 14 cases, respectively). Among MSI-H carcinomas, MLH1/MSH2 pattern of expression was significantly related to several clinical and pathological variables. In particular, MSI-H MLH1/MSH2-positive carcinomas were more often located in the distal colon, were more frequently classified as ordinary adenocarcinomas, and were more likely to be well or moderately differentiated, p53 positive, and <7 cm in diameter than were MLH1-negative and MSH2-negative carcinomas. In addition, MLH1-negative carcinomas were less common among patients with hereditary nonpolyposis colorectal cancer (HNPCC) or suspected HNPCC and in the group of patients aged <50 years. Patients with MLH1-negative carcinomas more frequently died of disease than did patients with MLH1/MSH2-positive and MSH2-negative MSI-H tumors, but the difference was not statistically significant. The results of the present investigation strongly indicate that immunohistochemical analysis of MLH1 and MSH2 expression is a practical and reliable method for the routine detection of the vast majority of MSI-H large bowel adenocarcinomas. Our data also point out that MSI-H MLH1/MSH2-positive colorectal carcinomas are characterized by distinctive pathological features.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118112     DOI: 10.1097/01.MP.0000018979.68686.B2

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  40 in total

Review 1.  The utility of immunohistochemical detection of DNA mismatch repair gene proteins.

Authors:  Jinru Shia; Nathan A Ellis; David S Klimstra
Journal:  Virchows Arch       Date:  2004-09-29       Impact factor: 4.064

2.  Novel MLH1 frameshift mutation in an extended hereditary nonpolyposis colorectal cancer family.

Authors:  Tanya-Kirilova Kadiyska; Radka-Petrova Kaneva; Dimitar-Georgiev Nedin; Alexandrina-Borisova Alexandrova; Antonina-Todorova Gegova; Stoyan-Ganchev Lalchev; Tatyana Christova; Vanio-Ivanov Mitev; Juergen Horst; Nadja Bogdanova; Ivo-Marinov Kremensky
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

Review 3.  Evolving role of gene expression signatures as biomarkers in early-stage colon cancer.

Authors:  Gaurav Goel
Journal:  J Gastrointest Cancer       Date:  2014-12

4.  EBV infection is associated with histone bivalent switch modifications in squamous epithelial cells.

Authors:  Merrin Man Long Leong; Arthur Kwok Leung Cheung; Wei Dai; Sai Wah Tsao; Chi Man Tsang; Christopher W Dawson; Josephine Mun Yee Ko; Maria Li Lung
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

5.  Mismatch repair protein expression in patients with stage II and III sporadic colorectal cancer.

Authors:  Lihua Zhao
Journal:  Oncol Lett       Date:  2018-03-23       Impact factor: 2.967

6.  MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer.

Authors:  Kota Momose; Makoto Yamasaki; Koji Tanaka; Yasuhiro Miyazaki; Tomoki Makino; Tsuyoshi Takahashi; Yukinori Kurokawa; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

7.  Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer?

Authors:  Britta Halvarsson; Annika Lindblom; Eva Rambech; Kristina Lagerstedt; Mef Nilbert
Journal:  Virchows Arch       Date:  2003-12-02       Impact factor: 4.064

8.  Reduced mRNA expression in paraffin-embedded tissue identifies MLH1- and MSH2-deficient colorectal tumours and potential mutation carriers.

Authors:  Annegret Müller; Dirk Zielinski; Nicolaus Friedrichs; Barbara Oberschmid; Sabine Merkelbach-Bruse; Hans K Schackert; Markus Linnebacher; Magnus von Knebel Doeberitz; Reinhard Büttner; Josef Rüschoff
Journal:  Virchows Arch       Date:  2008-06-26       Impact factor: 4.064

9.  Colorectal cancer in Iran: immunohistochemical profiles of four mismatch repair proteins.

Authors:  Mahsa Molaei; Babak Khoshkrood Mansoori; Somayeh Ghiasi; Fatemeh Khatami; Hamid Attarian; MohammadReza Zali
Journal:  Int J Colorectal Dis       Date:  2009-08-26       Impact factor: 2.571

Review 10.  [Molecular pathology in hereditary colorectal cancer. Recommendations of the Collaborative German Study Group on hereditary colorectal cancer funded by the German Cancer Aid (Deutsche Krebshilfe)].

Authors:  J Rüschoff; B Roggendorf; F Brasch; M Mathiak; D E Aust; J Plaschke; W Mueller; C Poremba; M Kloor; G Keller; M Muders; S Blasenbreu-Vogt; P Rümmele; A Müller; R Büttner
Journal:  Pathologe       Date:  2004-05       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.